Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial

M. M. Koeneman*, A. J. Kruse, L. F. S. Kooreman, A. zur Hausen, A. H. N. Hopman, S. J. S. Sep, T. Van Gorp, B. F. M. Slangen, H. J. van Beekhuizen, A. J. M. van de Sande, C. G. Gerestein, H. W. Nijman, R. F. P. M. Kruitwagen

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

The "TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia" (TOPIC) trial was stopped preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly due to a strong patient preference for either of the two treatment modalities. This prompted us to initiate a new study on the same subject, with a non-randomized, open-label design: the 'TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC)-3' study.

Original languageEnglish
Article number110
Number of pages2
JournalBMC Cancer
Volume17
DOIs
Publication statusPublished - 7 Feb 2017

Keywords

  • Cervical intraepithelial neoplasia
  • Imiquimod
  • Biological markers
  • Human papillomavirus
  • Natural history

Cite this